CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.
Rainbow will offer Color's hereditary cancer and heart health genetic risk assessment tests to patients in Hong Kong.
The study aims to understand the willingness of individuals with a clinical diagnosis of familial hypercholesterolemia and their family members to undergo confirmatory genetic testing.
The firm will provide its genetic testing, counseling, and cascade screening to patients seen at a group of US health systems, focusing on CDC Tier 1 conditions.
The New York Times reports that genetic screening is increasingly offered as an employee benefit.
A Color Genomics collaborator reported that nearly half of first-degree relatives who were invited for reduced-cost testing in cancer-related genes opted to participate.
The consumer genomics firm says employer benefits programs could expand access to BRCA1/2, Lynch syndrome, and FH genetic testing in the general population.
Bioage Labs now intends to set up an internal laboratory to experiment with different compounds, while building out its team.
The company plans to use proceeds to further invest in its development of molecular testing and other strategies in the preventive medicine space.
In PLOS this week: Mycobacterium abscessus linked to gastric conditions, placental gene expression changes associated with preterm birth, and more.
The Guardian reports that UK universities are looking into ways to reduce labs' reliance on single-use plastics.
People with certain gene variants tend to not like vegetables, particularly bitter ones, CNN reports.
MIT's Technology Review reports on a company's genetic test that gauges an embryo's susceptibility to certain diseases.